NASDAQ · PTGX
Healthcare · Biotechnology
$138.69
Down-$1.94 (-1.38%)
Updated Oct 7, 2026, 6:29 AM
SID Score
4.8/10
Composite research score
Smart Money
56/100
Neutral
Price performance · PTGX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
PTGX closed at $138.69 after 21 trading sessions, down 4.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $140.34 | $141.00 | $136.09 | $138.69 | 635.72K |
| Oct 5, 2026 | $139.96 | $142.51 | $138.08 | $140.63 | 1.27M |
| Oct 2, 2026 | $140.99 | $141.71 | $138.37 | $140.06 | 760.3K |
| Oct 1, 2026 | $139.23 | $143.68 | $138.37 | $139.19 | 886.25K |
| Sep 30, 2026 | $141.60 | $143.74 | $140.44 | $140.89 | 787.66K |
| Sep 29, 2026 | $143.45 | $144.09 | $138.88 | $140.97 | 508.01K |
| Sep 28, 2026 | $142.21 | $143.685 | $140.2401 | $142.44 | 925.46K |
| Sep 25, 2026 | $141.81 | $143.45 | $138.23 | $141.86 | 809.29K |
| Sep 24, 2026 | $138.76 | $140.80 | $134.10 | $137.34 | 989.23K |
| Sep 23, 2026 | $144.27 | $145.28 | $137.88 | $138.70 | 513.23K |
| Sep 22, 2026 | $144.64 | $147.71 | $144.50 | $145.07 | 806.18K |
| Sep 21, 2026 | $143.22 | $145.37 | $141.09 | $144.98 | 822.2K |
| Sep 18, 2026 | $143.09 | $144.58 | $140.435 | $143.00 | 1.84M |
| Sep 17, 2026 | $144.39 | $146.50 | $142.31 | $143.70 | 558.9K |
| Sep 16, 2026 | $144.19 | $146.19 | $140.88 | $142.84 | 507.31K |
| Sep 15, 2026 | $147.48 | $147.99 | $142.00 | $143.40 | 637.52K |
| Sep 14, 2026 | $150.23 | $151.24 | $146.83 | $147.78 | 608.02K |
| Sep 11, 2026 | $147.18 | $150.48 | $145.82 | $148.18 | 478.04K |
| Sep 10, 2026 | $143.29 | $146.51 | $142.00 | $145.16 | 543.13K |
| Sep 9, 2026 | $146.05 | $151.185 | $144.46 | $145.09 | 530.53K |
| Sep 8, 2026 | $143.61 | $147.29 | $142.00 | $145.94 | 700.13K |
The latest Smart Investors Daily articles mentioning PTGX.
Company
Market Activity
Research & News
PTGX research
Company profile and research snapshot.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | BMO Capital | Outperform | — |
| Sep 1, 2026 | Barclays | Overweight | — |
| Aug 31, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 31, 2026 | Citigroup | Buy | — |
| Aug 17, 2026 | BMO Capital | Outperform | — |
No generated briefing is available yet.
Benzinga · Sep 28, 2026
Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.99% on an annualized basis producing an average annual return of 20.58%. Currently, Protagonist Therapeutics has a market
ChartMill · Sep 23, 2026
PTGX screens strong on growth and setup: 47% EPS growth, no debt, and an 8/10 technical rating with a tight consolidation near resistance.
Yahoo · Sep 21, 2026
The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inade
Yahoo · Sep 18, 2026
JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PTGX.
